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Abstract
Objectives
The objective of this study is to evaluate the use of hydroxychloroquine and tocilizumab at the beginning 
of the COVID-19 pandemic and to describe the profile of patients who received these treatments.
Method
The medical records of 403 patients admitted for COVID-19 from March 1 to April 15, 2020 at the San 
Cecilio University Hospital (Granada, Spain) were analyzed. The data collected included sex, age, days 
hospitalized, previous pathologies and/or treatments, possible outcomes and drugs administered at the 
hospital. Student’s t-test and Pearson’s chi-square tests were used as statistical parameters to estimate the 
possible associations between the defined variables.
Results
Patients with a mean age of 66 years (standard deviation = 15.38), were hospitalized for an average of 15 
days (standard deviation = 12.89). The ICU admission rate was 9.93 %, and the death rate added up to 
17.37 % of the total number of patients. During the first wave of the pandemic, hydroxychloroquine was 
administered to the majority of hospitalized patients, while tocilizumab was restricted to the more severe 
cases.
Conclusions
The results showed two distinct trends in the use of the drugs studied. Tocilizumab was administered to 
a small number of patients, mainly those with longer length of stay or with complications. Hydroxychlo-
roquine was administered independently of the initial characteristics of patients, especially those who 
presented comorbidities or took multiple medications.
Keywords: COVID-19, SARS-CoV-2, tocilizumab, hydroxychloroquine, hospitalization.
1. Introduction
In December 2019, a case of atypical pneumonia of 
unknown origin was reported for the first time in 
Wuhan (China), which was later named as corona-
virus disease 19 (COVID-19). The etiological agent 
of this pathology is the coronavirus responsible 
for the severe acute respiratory syndrome (SARS-
CoV-2), which caused an unprecedented global 
pandemic with devastating consequences not only 
for public health, but for the economy (1). The main 
problem with SARS-CoV-2 was the combination of 
rapid spread and heterogeneous symptomatology 
that could lead to hospitalization or even death (2). 
Most patients diagnosed with COVID-19 were not 
severe cases, being asymptomatic or having com-
mon nonspecific symptoms such as fever, cough 
and myalgia (3). Nevertheless, those who develo-
ped complications like severe acute respiratory sy-
ndrome or infections were associated with increa-
sed admission to the ICU and high mortality (4). To 
reduce the morbidity and mortality rates associated 
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with COVID-19, pharmacological treatment of pa-
tients infected with SARS-CoV-2 became a priority. 
At the beginning of the pandemic, a large number 
of therapeutic agents were tested in search of new 
indications for drugs already approved by inter-
national organisations, such as the Food and Drug 
Administration (FDA) or the European Medicines 
Agency (EMA), while awaiting the development of 
an effective and safe vaccine (5).
In Spain, the first wave of the pandemic lasted 
from the beginning of March until June 2020 (6). 
The main drugs used to treat the disease in hos-
pitals and primary care centers were antimalarial 
medication (hydroxychloroquine [HCQ]), steroids 
(methylprednisolone) and antivirals (remdesivir), 
together with antibiotics in some cases. The use of 
interleukin 1 (IL-1) or 6 (IL-6) inhibitors, such as to-
cilizumab (TCZ), and Janus kinase inhibitors, such 
as ruxolitinib, is also worth mentioning. Several 
types of interferon (IFN), such as IFN-1b, were also 
used. Therefore, the trend during this period was 
the use of rather nonspecific agents, with the aim 
of avoiding the deterioration of the affected organs 
associated with the progression of the infection in 
patients (7). The combined administration of seve-
ral drugs was also widely used, such as HCQ cou-
pled with azithromycin in patients with comorbidi-
ties (8). In addition, nucleoside analogue antivirals, 
such as remdesivir, were used in high-risk groups. 
This reduced the viral load, but it did not conside-
rably improve symptomatology (9).
Among the drugs with a new indication was HCQ 
stood out, an antimalarial drug also used to treat 
lupus and arthritis. The evidence supporting the 
indication for this drug was based on its used in 
previous SARS-CoV-1 outbreaks (11) and on the si-
milarity of COVID-19 to other inflammatory patho-
logies. Initially, both HCQ and chloroquine (CQ) 
were mostly used in more severe cases (12). Ano-
ther relevant drug during the pandemic was TCZ. 
At first, its used was avoided due to the uncertain-
ties raised in the scientific literature (13). The studies 
that sought to determine the effectiveness of this 
drug against COVID-19 did not show significant 
variations with respect to other treatments (14, 15). 
However, as the pandemic progressed, the number 
of individuals receiving TCZ and the knowledge of 
this drug increased simultaneously (16-18).
As such, we set out to determine the role of these 
two drugs during the first wave of the pandemic and 
their association with other variables of interest. The 
objective of this longitudinal observational study 
was to evaluate the use of HCQ and TCZ during this 
period in Spain and ultimately to describe the profile 
of the patients who received these treatments.
2. Materials and methods
2.1. Design
The planning and development of this longitudinal 
observational study was made following the Stren-
gthening the Reporting of Observational Studies in Epi-
demiology (STROBE) guidelines. The retrospective 
analysis was carried out on data provided by the San 
Cecilio University Hospital (Granada, Spain) and co-
rresponds to 441 patients hospitalized for COVID-19 
in this facility from March 1 to April 15, 2020. From 
the database provided, individuals with an incom-
plete medical history were discarded, resulting in a 
final sample of 403 patients. The registry of variables 
included baseline characteristics and possible outco-
mes, as well as drugs used for each patient (Figure 1).
2.2. Variables
All patient-related information was obtained from 
electronic medical records where the following va-
riables were included:
• Patient’s general information: age, sex and 
country of origin.
• Hospitalization data: date of admission date to 
the center; date of discharge from the center or, 
otherwise, date of death; CURB-65 score; co-
morbidity; need for admission to the ICU and 
number of days hospitalized.
• Medical records of previous diseases: hyper-
tension (HT), diabetes (DM), pneumological 
pathologies, chronic kidney failure (CKF), 
cardiovascular diseases (CVD), autoimmune 
diseases, neoplasms, asthma and chronic obs-
tructive pulmonary disease (COPD). Also in-
cluded in this section were current treatments 
associated with underlying pathologies, going 
from immunosuppressants to biologic drugs, 
as well as polypharmacy. 
• Records of medication administered during 
hospitalization: HCQ, corticosteroids boluses 
(CTC), lopinavir/ritonavir, azithromycin, an-
giotensin-converting enzyme inhibitors (ACE 
inhibitors) or angiotensin II receptor antago-
nists (ARA2), antibiotics and TCZ. This sec-
tion also included if the occurrence of cyto-
kine release syndrome (CRS) or the need for 
cardiopulmonary resuscitation (CPR) when 
admitted to the hospital.
• Dependency and domiciliary records.
2.3. Statistical analysis
The statistical analysis of the data was made using 
two analysis software packages: IBM SPSS ® (V.26) 
and R (R Foundation for Statistical Computing, 
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Wien, Austria), V.4.0.4. The relationship between 
the variables previously mentioned and the drugs 
of interest was evaluated using the following sta-
tistical parameters: Student’s t-tests and Pearson’s 
chi-square tests, with a 95% confidence interval in 
all the analyses.
2.4. Ethical considerations
The provincial Research Ethics Committee of Gra-
nada approved this study on October 1, 2020. The 
database used was anonymized, in compliance 
with the Declaration of Helsinki.
3. Results
The study population consisted of 403 individuals, 
of whom 55.33% were male and 44.67% female. The 
mean age of the patients in the sample was 66 years, 
with a standard deviation (SD) of 15.38. The avera-
ge length of hospitalization was 15 days (SD=12.89). 
Despite the high incidence of hospitalization, only 
40 patients (9.9%) required admission to the ICU. 
Similarly, only 17.4% of the subjects had a fatal out-
come, amounting to 70 deaths. It should be noted 
that 69.73% of the patients had some previous pa-
thology, and 285 of the total number of patients re-
quired CPR at the time of admission (Table 1).
3.1. Relationship between length of hospital stay 
and use of a given drug
Before starting the in-depth analysis of the drugs 
under study, the relationship between the adminis-
tration of a given drug and the number of days of 
hospitalization was determined. According to the 
results obtained, HCQ was used for a wide range 
of individuals, regardless of the number of days of 
hospitalization. In turn, TCZ, CTC, antibiotics and 
the ACE inhibitors/ARA2 combination were the 
preferred options for those patients who remained 
longer in hospital, as shown in Figure 2.
3.2. Tocilizumab 
TCZ (Table 2) was administered to 59 patients 
(14.6% of the total number of subjects). Data sug-
gests an association with its use in men (p<0.001). 
A relationship was also established between TCZ 
use and age (p=0.009), with a mean value of 60 
years (SD=11.68). Regarding the hospitalization 
period, patients treated with this drug remained 
hospitalized longer than those who did not receive 
it (p<0.001). In addition, the joint use of TCZ with 
other drugs of preferential use in long-stay patients 
was analyzed. As a result, an association was obser-
ved in the coadministration of the drug with anti-
biotics (p=0.006).
Since prolonged hospitalization could be related to 
the worsening of symptoms and the referral to in-
tensive care, the correlation between the use of TCZ 
and admission to the ICU was studied. As expected, 
there was an association between drug administra-
tion and the need for intensive care (p<0.001). The 
majority of patients treated with TCZ required CPR 
at the time of admission (p<0.001). Similarly, 57 of 
the 59 patients who received the drug eventually 
presented CRS during hospitalization (p<0.001). 
Considering this finding, a relation in the joint use 
of TCZ and CTC was determined, with a p-value of 
<0.001.
Finally, other risk factors that could be involved in 
the worsening of the disease were analyzed. In con-
trast to previous results, it was not possible to relate 
TCZ use with the presence of comorbidities at the 
time admission to the hospital (p=0.512), nor was it 
associated with other drugs in patients taking mul-
tiple medications prior hospitalization (p=0.388).
3.3. Hydroxychloroquine
The other drug under study was HCQ. It was admi-
nistered to 350 out of the 403 patients, that is, 86.8% 
of the patients admitted for COVID-19. This group 
comprised 197 males and 153 females. The statistical 
analysis performed found no association between 
sex and drug administration (p=0.324), showing 
that HCQ was used irrespective of sex (Table 3). 
Despite its extensive use, HCQ failed to significant-
ly reduce the length of hospital stay (p=0.136). The 
average number of days hospitalized was similar 
in those treated and not treated with HCQ. In ad-
dition, those who were eventually admitted to the 
ICU were treated with HCQ in a similar proportion 
to those who remained on the ward. No direct asso-
ciation was established between referral to intensi-
ve care and the use of this drug (p=0.898).
Unlike the previous variables, an association was 
found between comorbidity and HCQ use (p=0.01). 
Considering this finding, the relationship between 
HCQ use and patients with previous at the time of 
admission to the hospital was also tested. A correla-
tion was observed between individuals who recei-
ved the drug and who presented HT (p=0.003), CKF 
(p=0.002) or CVD (p<0.001). Accordingly, patients 
who needed CPR at the time of admission received 
HCQ in a higher proportion than the rest of patients 
(p<0.001). Patients with comorbidities required 
specific treatments for their pathologies. Therefore, 
the relationship between drug administration and 
multiple medications was tested, with a p-value of 
0.002.
Finally, the correlation between HCQ and the use 
of other therapeutic agents administered in the hos-
pital was analyzed. An association was found be-
tween in the joint use of HCQ and CTC (p=0.002), 
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azithromycin (p<0.001) and lopinavir/ritonavir 
(p<0.001), which were used regardless of the num-
ber of days of hospitalization.
4. Discussion
4.1. Relationship between length of hospital stay 
and use of a given drug
Based on the results, it was observed that TCZ, 
CTCs, ACE /ARA2 inhibitors and antibiotics were 
preferentially used in patients with a longer hos-
pital stay. The choice of these drugs was based on 
the improvement of symtoms. TCZ is an agent that 
blocks the binding of IL-6 to its receptor, leading 
to a decrease in the effects of this proinflammatory 
cytokine (19). CTCs, especially glucocorticoids, 
were also administered due to their ability to redu-
ce the CRS associated with COVID-19 in patients 
who manifest hemophagocytic syndrome (HPS) 
and macrophage activation syndrome (MAS) (16). 
Regarding the use of ACE/ARA2 inhibitors, there 
were no standardized criteria, as the interaction of 
SARS-CoV-2 with the Renin-Angiotensin-Aldoste-
rone system was not fully clear. For this reason, al-
though some authors rejected the use of these drugs 
in COVID-19 patients (20), scientific evidence proo-
fs HT treatment a priority (20, 21). Finally, antibiotic 
treatment was reserved for patients who presented 
nonspecific symptoms not associated with the di-
sease or patients with complications (22).
4.2. Tocilizumab
The data obtained from analysing TCZ showed 
a trend in the use of this drug in patients with a 
longer hospital stay and consequent referral to the 
ICU. In fact, a relevant association was found in the 
joint use of TCZ and antibiotics. These antimicro-
bial agents were administered to a greater extent to 
individuals hospitalized for extended periods, as 
observed previously (15).
Regarding the use of TCZ in the ICU, admission to 
intensive care was associated with a worsening of 
the disease. This description matched the findings 
of other studies in which patients who received TCZ 
presented poorer health and old age (23, 24). Requi-
ring CPR at admission served as an indicator of pa-
tients at higher risk of severe COVID-19. The fact that 
TCZ was preferentially used for this group of patients 
supports what was observed in previous studies (25).
In addition, TCZ was used almost exclusively for 
individuals who presented CRS at any time during 
hospitalization. Given this information, an associa-
tion was found between the use of the drug in con-
junction with CTC, which were widely indicated to 
treat this complication (16). However, when evalua-
ting the coadministration of TCZ with other drugs 
in the patients under study, no correlation could be 
established. The explanation for this could be owed 
to the restricted use of the drug, as there is no evi-
dence of contraindications in the joint use of TCZ 
and other therapeutic agents (26, 27, 28).
With all the information obtained from the analysis, 
it was possible to preliminarily describe the TCZ 
target patient in the cohort studied. Generic featu-
res included a mean age of 60 years, extended hos-
pital stay associated with ICU admission or worse-
ning of the disease, and the occurrence of CRS.
4.3. Hydroxychloroquine
The results regarding HCQ showed a wide use of 
the drug regardless of the baseline characteristics 
of the patients. This trend was common during the 
beginning of the pandemic and was based on re-
commendations that positioned it as one of the best 
choices against SARS-CoV-2 (29).
Regarding the most relevant associations, a correla-
tion was observed between the presence of two or 
more diseases at the time of admission and the in-
dication for HCQ. When examining the pathologies 
included among comorbidities, an association was 
found between the drug and HT, CVD and CKD. 
As described by other authors (30), both HT and the 
complications derived from it, which constitute the 
majority of CVD cases, require chronic treatment. 
Therefore, patients with these pathologies genera-
lly receive multiple medications.
The relationship between subjects receiving multiple 
medications and the administration of HCQ was tes-
ted and a relevant association was found. The reason 
for this result could be the widespread use of the drug 
during the first wave of the pandemic (12) rather than 
the protective effects on this group of patients. None-
theless, a correlation was observed between the joint 
administration of HCQ and azithromycin, an effective 
combination supported by scientific evidence (31).
The data obtained from the analysis enables the pro-
filing of patients who received HCQ during hospita-
lization. The general characteristics of these subjects 
were: a mean age of 64 years, generally presenting 
pathologies such as HT, CKD and CVD, and, to a les-
ser extent, patients receiving multiple medications.
4.4. Limitations
The study has certain limitations inherent to its ob-
servational nature. Other than these, the small sam-
ple size (n=403) due to exclusion criteria and the 
short period of data collection are worth noting. Al-
though these characteristics could imply a possible 
imprecision bias with regard to the generalization 
of the results, the strength of the statistical parame-
ters used increases their validity (7).
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5. Conclusions
The results showed two totally different trends in 
the use of the drugs under study. On the one hand, 
TCZ was administered to a very small number of 
the total number of subjects. It was mainly indica-
ted for those who remained hospitalized longer or 
whose clinical conditions worsened. Its use was also 
associated with ICU patients in coadministration 
with antibiotics. On the other hand, HCQ became 
one of the most widely used therapeutic agents re-
gardless of the initial characteristics of the patients. 
It became particularly relevant for patients with co-
morbidities or receiving multiple medications. In 
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TABLES
Table 1. Descriptive analysis of the main variables: sex, admission to the ICU, death, presence of comorbidities 
and possible need for CPR. Data expressed as absolute value and percentage of the total (n=403).
Data expressed as absolute and relative values for qualitative variables, or as mean and standard deviation (SD) for quantitative variables. 
P-value was obtained after statistical analysis using Student’s t test and Pearson’s chi-square tests, with a 95% confidence interval.
Table 2. Association between tocilizumab (TCZ) administration with the corresponding variables 
(sex, age, days hospitalized, admission to the ICU, comorbidities and death)
















Data expressed as absolute and relative values for qualitative variables, or as mean and standard deviation (SD) for quantitative variables. 
P-value was obtained after statistical analysis using Student’s t test and Pearson’s chi-square tests, with a 95% confidence interval.
Tabla 3. Association between hydroxychloroquine administration (HCQ) and the corresponding 






Men 46 (20.63%) 177 (79.37%)
<0.001
Women 13 (7.22%) 167 (92.78%)
Age 60.19 (SD=11.68) 67.13 (SD=15.73) 0.009
Days hospitalized 23.85 (SD=20.54) 13.10 (SD=10.31) <0.001
ICU
Admitted 19 (47.5%) 21 (52.5%)
<0.001
Not admitted 40 (11.02%) 323 (88.98%)
Comorbidities
Present 39 (13.88%) 242 (86.12%)
0.512
Absent 20 (16.39%) 102 (83.61%)
Outcome
Discharged 51 (15.32%) 282 (84.68%)
0.403






Men 197 (88.34%) 26 (11.66%)
0.324
Women 153 (85%) 27 (15%)
Age 64.37 (SD=14.26) 77.66 (SD=17.57) 0.164
Days hospitalized 14.72 (SD=12.52) 14.38 (SD=15.23) 0.136
ICU
Admitted 35 (87.5%) 5 (12.5%)
0.898
Not admitted 315 (86.78%) 48 (13.22%)
Comorbidities
Present 236 (83.99%) 45 (16.01%)
0.010
Absent 114 (93.44%) 8 (6.56%)
Outcome
Discharged 302 (90.69%) 31 (9.31%)
<0.001
Death 48 (68.57%) 22 (31.43%)
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FIGURES
Figure 1. Flowchart for cohort selection. Data expressed as absolute values.
Hydroxychloroquine (HCQ), corticosteroids boluses (CTC), tocilizumab (TCZ), angiotensin-converting enzyme inhibitors (ACE inhibitors, 
angiotensin II receptor antagonists (ARA2). Data expressed as number of days vs. administration/non-administration of each treatment.
 
Figure 2. Representation of length of hospital stay of admitted patients and administration of specific drugs (n = 403).
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